Watch: Biotech Going Up Against Big Pharma

As co-founder, chairman & chief executive of Ocugen, Shankar Musunuri, is looking to bring eye disease products to the patients that big pharma’s drugs have left out. The Malvern, Penn.-based company has four compounds in its pipeline at various stages of development. It’s most advanced candidate, OCU300, is gearing up for Phase III trials in 2018. It’s second candidate, OCU310, combines brimonidine, a drug usually designed for patients with glaucoma, and a steroid. With some of Ocugen’s products, like it’s OCU100 compound designed to delay the progression of retinitis pigmentosa, there is no other drug currently on the market – so there’s no immediate competition. “The goal is to get something to the market to help patients as soon as possible because they don’t have anything today,”

Follow us on social media for the latest updates in B2B!

Image

Latest

teacher
Building the Next Generation of Educators Through Apprenticeship Pathways and Workforce-Aligned Training
March 23, 2026

Teacher shortages aren’t exactly a new headline—but lately, they’ve started to feel a lot more urgent. In some places, schools have gone years without enough fully trained teachers in the classroom, exposing real flaws in how we prepare and retain educators. Add in the rising cost of becoming a teacher and training models that haven’t…

Read More
Joint Commission 360
Understanding Joint Commission 360 Standards: What They Mean for SPD Teams (Part 1)
March 17, 2026

For a long time, compliance in healthcare was tied to the survey cycle. Now, that model is shifting. With the introduction of Joint Commission 360, organizations are being asked to demonstrate continuous performance—not just preparedness. As patient safety comes under increasing scrutiny, The Joint Commission is moving toward an approach built on real-time data, traceability,…

Read More
university
The Employer University Alignment Journey with Kristen Fox, CEO of Business-Higher Education Forum
March 16, 2026

Across the U.S., the conversation about the value of a college degree is increasingly tied to one central question: Does higher education actually prepare students for the workforce? As artificial intelligence reshapes how work gets done and employers rethink the skills they need, universities are under growing pressure to ensure graduates leave not just…

Read More
private equity
How AI Is Transforming Private Equity Deal Evaluation and Portfolio Strategy
March 13, 2026

Artificial intelligence is rapidly transforming how organizations evaluate risk, analyze markets, and drive operational efficiency. In financial services alone, global AI spending is projected to surpass $97 billion by 2027, reflecting how deeply data-driven technologies are reshaping decision-making. For private equity firms—where hundreds of potential investments may be screened each year—the ability to analyze information…

Read More